ID   STK3_HUMAN              Reviewed;         491 AA.
AC   Q13188; A8K722; B3KYA7; Q15445; Q15801; Q96FM6;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   26-APR-2004, sequence version 2.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=Serine/threonine-protein kinase 3;
DE            EC=2.7.11.1;
DE   AltName: Full=Mammalian STE20-like protein kinase 2;
DE            Short=MST-2;
DE   AltName: Full=STE20-like kinase MST2;
DE   AltName: Full=Serine/threonine-protein kinase Krs-1;
DE   Contains:
DE     RecName: Full=Serine/threonine-protein kinase 3 36kDa subunit;
DE              Short=MST2/N;
DE   Contains:
DE     RecName: Full=Serine/threonine-protein kinase 3 20kDa subunit;
DE              Short=MST2/C;
GN   Name=STK3; Synonyms=KRS1, MST2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AUTOPHOSPHORYLATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=8566796; DOI=10.1016/0378-1119(95)00653-2;
RA   Creasy C.L., Chernoff J.;
RT   "Cloning and characterization of a member of the MST subfamily of
RT   Ste20-like kinases.";
RL   Gene 167:303-306(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=8816758; DOI=10.1073/pnas.93.19.10099;
RA   Taylor L.K., Wang H.C., Erikson R.L.;
RT   "Newly identified stress-responsive protein kinases, Krs-1 and Krs-
RT   2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10099-10104(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-8; 13-43; 57-69; 85-91; 115-128; 133-141;
RP   149-178; 229-256; 267-298; 329-338; 382-403; 423-451; 462-467 AND
RP   474-485, ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary carcinoma;
RA   Bienvenut W.V., Matallanas D., Cooper W.N., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 96-203.
RX   PubMed=8274451;
RA   Schultz S.J., Nigg E.A.;
RT   "Identification of 21 novel human protein kinases, including 3 members
RT   of a family related to the cell cycle regulator nimA of Aspergillus
RT   nidulans.";
RL   Cell Growth Differ. 4:821-830(1993).
RN   [9]
RP   PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-322.
RX   PubMed=11278283; DOI=10.1074/jbc.M005109200;
RA   Lee K.-K., Ohyama T., Yajima N., Tsubuki S., Yonehara S.;
RT   "MST, a physiological caspase substrate, highly sensitizes apoptosis
RT   both upstream and downstream of caspase activation.";
RL   J. Biol. Chem. 276:19276-19285(2001).
RN   [10]
RP   INTERACTION WITH RAF1, AND ENZYME REGULATION.
RX   PubMed=15618521; DOI=10.1126/science.1103233;
RA   O'Neill E., Rushworth L., Baccarini M., Kolch W.;
RT   "Role of the kinase MST2 in suppression of apoptosis by the proto-
RT   oncogene product Raf-1.";
RL   Science 306:2267-2270(2004).
RN   [11]
RP   INTERACTION WITH SAV1, AND FUNCTION.
RX   PubMed=15688006; DOI=10.1038/sj.onc.1208445;
RA   Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A.,
RA   Nigg E.A., Sillje H.H.W.;
RT   "The Ste20-like kinase Mst2 activates the human large tumor suppressor
RT   kinase Lats1.";
RL   Oncogene 24:2076-2086(2005).
RN   [12]
RP   INTERACTION WITH RASSF1.
RX   PubMed=16510573; DOI=10.1158/0008-5472.CAN-05-2951;
RA   Oh H.J., Lee K.-K., Song S.J., Jin M.S., Song M.S., Lee J.H., Im C.R.,
RA   Lee J.-O., Yonehara S., Lim D.-S.;
RT   "Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis.";
RL   Cancer Res. 66:2562-2569(2006).
RN   [13]
RP   FUNCTION, INTERACTION WITH SAV1, AND MUTAGENESIS OF LYS-56.
RX   PubMed=16930133; DOI=10.1111/j.1742-4658.2006.05427.x;
RA   Callus B.A., Verhagen A.M., Vaux D.L.;
RT   "Association of mammalian sterile twenty kinases, Mst1 and Mst2, with
RT   hSalvador via C-terminal coiled-coil domains, leads to its
RT   stabilization and phosphorylation.";
RL   FEBS J. 273:4264-4276(2006).
RN   [14]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=18328708; DOI=10.1016/j.cub.2008.02.006;
RA   Praskova M., Xia F., Avruch J.;
RT   "MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell
RT   proliferation.";
RL   Curr. Biol. 18:311-321(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316 AND SER-444, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH STK38 AND MOBKL1B.
RX   PubMed=18362890; DOI=10.1038/onc.2008.66;
RA   Hirabayashi S., Nakagawa K., Sumita K., Hidaka S., Kawai T., Ikeda M.,
RA   Kawata A., Ohno K., Hata Y.;
RT   "Threonine 74 of MOB1 is a putative key phosphorylation site by MST2
RT   to form the scaffold to activate nuclear Dbf2-related kinase 1.";
RL   Oncogene 27:4281-4292(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   REVIEW.
RX   PubMed=19484742; DOI=10.1002/biof.47;
RA   Hergovich A., Hemmings B.A.;
RT   "Mammalian NDR/LATS protein kinases in hippo tumor suppressor
RT   signaling.";
RL   BioFactors 35:338-345(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-15; SER-316; THR-336 AND
RP   SER-444, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION, INTERACTION WITH RASSF2, AND SUBCELLULAR LOCATION.
RX   PubMed=19525978; DOI=10.1038/onc.2009.152;
RA   Cooper W.N., Hesson L.B., Matallanas D., Dallol A., von Kriegsheim A.,
RA   Ward R., Kolch W., Latif F.;
RT   "RASSF2 associates with and stabilizes the proapoptotic kinase MST2.";
RL   Oncogene 28:2988-2998(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   PHOSPHORYLATION AT THR-117 AND THR-384, AND INTERACTION WITH PKB/AKT1.
RX   PubMed=20086174; DOI=10.1158/0008-5472.CAN-09-3147;
RA   Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W.;
RT   "Proapoptotic kinase MST2 coordinates signaling crosstalk between
RT   RASSF1A, Raf-1, and Akt.";
RL   Cancer Res. 70:1195-1203(2010).
RN   [24]
RP   FUNCTION.
RX   PubMed=20212043; DOI=10.1074/jbc.M109.078915;
RA   Kilili G.K., Kyriakis J.M.;
RT   "Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK
RT   pathway activity via maintenance of protein phosphatase-2A catalytic
RT   subunit levels and consequent suppression of inhibitory Raf-1
RT   phosphorylation.";
RL   J. Biol. Chem. 285:15076-15087(2010).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH NEK2.
RX   PubMed=21076410; DOI=10.1038/ncb2120;
RA   Mardin B.R., Lange C., Baxter J.E., Hardy T., Scholz S.R., Fry A.M.,
RA   Schiebel E.;
RT   "Components of the Hippo pathway cooperate with Nek2 kinase to
RT   regulate centrosome disjunction.";
RL   Nat. Cell Biol. 12:1166-1176(2010).
RN   [26]
RP   PHOSPHORYLATION AT THR-117, AND INTERACTION WITH PKB/AKT1.
RX   PubMed=20231902; DOI=10.1371/journal.pone.0009616;
RA   Kim D., Shu S., Coppola M.D., Kaneko S., Yuan Z.Q., Cheng J.Q.;
RT   "Regulation of proapoptotic mammalian ste20-like kinase MST2 by the
RT   IGF1-Akt pathway.";
RL   PLoS ONE 5:E9616-E9616(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   INTERACTION WITH RASSF1, AND ENZYME REGULATION.
RX   PubMed=21199877; DOI=10.1074/jbc.M110.178210;
RA   Guo C., Zhang X., Pfeifer G.P.;
RT   "The tumor suppressor RASSF1A prevents dephosphorylation of the
RT   mammalian STE20-like kinases MST1 and MST2.";
RL   J. Biol. Chem. 286:6253-6261(2011).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH ESR1.
RX   PubMed=21104395; DOI=10.1007/s00109-010-0698-y;
RA   Park Y., Park J., Lee Y., Lim W., Oh B.C., Shin C., Kim W., Lee Y.;
RT   "Mammalian MST2 kinase and human Salvador activate and reduce estrogen
RT   receptor alpha in the absence of ligand.";
RL   J. Mol. Med. 89:181-191(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-316; THR-336 AND
RP   SER-385, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-60.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Stress-activated, pro-apoptotic kinase which, following
CC       caspase-cleavage, enters the nucleus and induces chromatin
CC       condensation followed by internucleosomal DNA fragmentation. Key
CC       component of the Hippo signaling pathway which plays a pivotal
CC       role in organ size control and tumor suppression by restricting
CC       proliferation and promoting apoptosis. The core of this pathway is
CC       composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in
CC       complex with its regulatory protein SAV1, phosphorylates and
CC       activates LATS1/2 in complex with its regulatory protein MOB1,
CC       which in turn phosphorylates and inactivates YAP1 oncoprotein and
CC       WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its
CC       translocation into the nucleus to regulate cellular genes
CC       important for cell proliferation, cell death, and cell migration.
CC       STK3/MST2 and STK4/MST1 are required to repress proliferation of
CC       mature hepatocytes, to prevent activation of facultative adult
CC       liver stem cells (oval cells), and to inhibit tumor formation.
CC       Phosphorylates NKX2-1 (By similarity). Phosphorylates NEK2 and
CC       plays a role in centrosome disjunction by regulating the
CC       localization of NEK2 to centrosome, and its ability to
CC       phosphorylate CROCC and CEP250. In conjunction with SAV1,
CC       activates the transcriptional activity of ESR1 through the
CC       modulation of its phosphorylation. Positively regulates RAF1
CC       activation via suppression of the inhibitory phosphorylation of
CC       RAF1 on 'Ser-259'. Phosphorylates MOBKL1A and RASSF2.
CC       Phosphorylates MOBKL1B on 'Thr-74'. Acts cooperatively with
CC       MOBKL1B to activate STK38. {ECO:0000250,
CC       ECO:0000269|PubMed:15688006, ECO:0000269|PubMed:16930133,
CC       ECO:0000269|PubMed:18328708, ECO:0000269|PubMed:18362890,
CC       ECO:0000269|PubMed:19525978, ECO:0000269|PubMed:20212043,
CC       ECO:0000269|PubMed:21076410, ECO:0000269|PubMed:21104395,
CC       ECO:0000269|PubMed:8566796, ECO:0000269|PubMed:8816758}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Inhibited by the C-terminal non-catalytic
CC       region. Activated by caspase-cleavage. Full activation also
CC       requires homodimerization and autophosphorylation of Thr-180,
CC       which are inhibited by the proto-oncogene product RAF1. Activated
CC       by RASSF1 which acts by preventing its dephosphorylation.
CC       {ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:21199877}.
CC   -!- SUBUNIT: Homodimer; mediated via the coiled-coil region. Interacts
CC       with NORE1, which inhibits autoactivation (By similarity).
CC       Interacts with and stabilizes SAV1. Interacts with RAF1, which
CC       prevents dimerization and phosphorylation. Interacts with RASSF1.
CC       Interacts (via SARAH domain) with isoform 1 of NEK2. Interacts
CC       with ESR1 only in the presence of SAV1. Interacts with PKB/AKT1.
CC       Forms a tripartite complex with MOBKL1B and STK38. Interacts with
CC       RASSF2 (via SARAH domain). {ECO:0000250,
CC       ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15688006,
CC       ECO:0000269|PubMed:16510573, ECO:0000269|PubMed:16930133,
CC       ECO:0000269|PubMed:18362890, ECO:0000269|PubMed:19525978,
CC       ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902,
CC       ECO:0000269|PubMed:21076410, ECO:0000269|PubMed:21104395,
CC       ECO:0000269|PubMed:21199877}.
CC   -!- INTERACTION:
CC       Q8IZU0:FAM9B; NbExp=3; IntAct=EBI-992580, EBI-10175124;
CC       Q53SE7:FLJ13057; NbExp=3; IntAct=EBI-992580, EBI-10172181;
CC       O95166:GABARAP; NbExp=2; IntAct=EBI-992580, EBI-712001;
CC       Q9H0R8:GABARAPL1; NbExp=2; IntAct=EBI-992580, EBI-746969;
CC       P60520:GABARAPL2; NbExp=2; IntAct=EBI-992580, EBI-720116;
CC       Q99259:GAD1; NbExp=3; IntAct=EBI-992580, EBI-743184;
CC       Q9GZQ8:MAP1LC3B; NbExp=5; IntAct=EBI-992580, EBI-373144;
CC       Q9BXW4:MAP1LC3C; NbExp=2; IntAct=EBI-992580, EBI-2603996;
CC       Q7L9L4:MOB1B; NbExp=4; IntAct=EBI-992580, EBI-2558745;
CC       Q9NS23-2:RASSF1; NbExp=5; IntAct=EBI-992580, EBI-438698;
CC       P50749:RASSF2; NbExp=13; IntAct=EBI-992580, EBI-960081;
CC       Q86WH2:RASSF3; NbExp=6; IntAct=EBI-992580, EBI-2845202;
CC       Q9H2L5:RASSF4; NbExp=8; IntAct=EBI-992580, EBI-2933362;
CC       Q8WWW0:RASSF5; NbExp=7; IntAct=EBI-992580, EBI-367390;
CC       Q9H4B6:SAV1; NbExp=19; IntAct=EBI-992580, EBI-1017775;
CC       Q14BN4:SLMAP; NbExp=6; IntAct=EBI-992580, EBI-1043216;
CC       Q13043:STK4; NbExp=17; IntAct=EBI-992580, EBI-367376;
CC       G5E9B5:TFPT; NbExp=3; IntAct=EBI-992580, EBI-10178002;
CC       Q13077:TRAF1; NbExp=5; IntAct=EBI-992580, EBI-359224;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Note=The caspase-cleaved form cycles between
CC       nucleus and cytoplasm (By similarity). Phosphorylation at Thr-117
CC       leads to inhibition of nuclear translocation. {ECO:0000250,
CC       ECO:0000269|PubMed:19525978}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13188-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13188-2; Sequence=VSP_054167;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in adult kidney,
CC       skeletal and placenta tissues and at very low levels in adult
CC       heart, lung and brain tissues. {ECO:0000269|PubMed:8566796}.
CC   -!- INDUCTION: Activity increases during mitosis.
CC       {ECO:0000269|PubMed:18328708}.
CC   -!- PTM: Phosphorylation at Thr-117 and Thr-384 by PKB/AKT1, leads to
CC       inhibition of its: cleavage, kinase activity, autophosphorylation
CC       at Thr-180, binding to RASSF1 and nuclear translocation, and
CC       increase in its binding to RAF1. {ECO:0000269|PubMed:11278283,
CC       ECO:0000269|PubMed:20086174, ECO:0000269|PubMed:20231902}.
CC   -!- PTM: Proteolytically cleaved by caspase-3 during apoptosis.
CC       Proteolytic cleavage results in kinase activation and nuclear
CC       translocation of the truncated form (MST1/N).
CC       {ECO:0000269|PubMed:11278283}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U26424; AAC50386.1; -; mRNA.
DR   EMBL; U60206; AAB17261.1; -; mRNA.
DR   EMBL; AK131363; BAG54769.1; -; mRNA.
DR   EMBL; AK291837; BAF84526.1; -; mRNA.
DR   EMBL; AC016877; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP002087; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003355; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003467; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003551; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW91781.1; -; Genomic_DNA.
DR   EMBL; BC010640; AAH10640.1; -; mRNA.
DR   EMBL; Z25422; CAA80909.1; -; mRNA.
DR   CCDS; CCDS47900.1; -. [Q13188-1]
DR   CCDS; CCDS59108.1; -. [Q13188-2]
DR   PIR; I38212; I38212.
DR   RefSeq; NP_001243241.1; NM_001256312.1. [Q13188-2]
DR   RefSeq; NP_006272.2; NM_006281.3. [Q13188-1]
DR   UniGene; Hs.492333; -.
DR   UniGene; Hs.738869; -.
DR   PDB; 3WWS; X-ray; 2.01 A; A/B/C/D=436-484.
DR   PDB; 4HKD; X-ray; 1.50 A; A/B/C/D=436-484.
DR   PDB; 4L0N; X-ray; 1.40 A; A/B/C/D/E/F/G/H/I/J=436-484.
DR   PDB; 4LG4; X-ray; 2.42 A; A/B/C/D/E/F=16-313.
DR   PDB; 4LGD; X-ray; 3.05 A; A/B/C/D=9-491.
DR   PDB; 4OH9; X-ray; 1.70 A; A/B=436-484.
DR   PDB; 5BRM; X-ray; 2.65 A; G/H/I/J/K/L/M/N/O=371-401.
DR   PDB; 5DH3; X-ray; 2.47 A; A/B=15-313.
DR   PDBsum; 3WWS; -.
DR   PDBsum; 4HKD; -.
DR   PDBsum; 4L0N; -.
DR   PDBsum; 4LG4; -.
DR   PDBsum; 4LGD; -.
DR   PDBsum; 4OH9; -.
DR   PDBsum; 5BRM; -.
DR   PDBsum; 5DH3; -.
DR   ProteinModelPortal; Q13188; -.
DR   SMR; Q13188; -.
DR   BioGrid; 112664; 89.
DR   DIP; DIP-36128N; -.
DR   IntAct; Q13188; 81.
DR   MINT; MINT-3027356; -.
DR   STRING; 9606.ENSP00000390500; -.
DR   BindingDB; Q13188; -.
DR   ChEMBL; CHEMBL4708; -.
DR   GuidetoPHARMACOLOGY; 2219; -.
DR   iPTMnet; Q13188; -.
DR   PhosphoSitePlus; Q13188; -.
DR   BioMuta; STK3; -.
DR   DMDM; 46577700; -.
DR   OGP; Q13188; -.
DR   EPD; Q13188; -.
DR   MaxQB; Q13188; -.
DR   PaxDb; Q13188; -.
DR   PeptideAtlas; Q13188; -.
DR   PRIDE; Q13188; -.
DR   DNASU; 6788; -.
DR   Ensembl; ENST00000419617; ENSP00000390500; ENSG00000104375. [Q13188-1]
DR   Ensembl; ENST00000523601; ENSP00000429744; ENSG00000104375. [Q13188-2]
DR   GeneID; 6788; -.
DR   KEGG; hsa:6788; -.
DR   UCSC; uc003yio.5; human. [Q13188-1]
DR   CTD; 6788; -.
DR   DisGeNET; 6788; -.
DR   GeneCards; STK3; -.
DR   HGNC; HGNC:11406; STK3.
DR   HPA; CAB025316; -.
DR   HPA; HPA007120; -.
DR   MIM; 605030; gene.
DR   neXtProt; NX_Q13188; -.
DR   OpenTargets; ENSG00000104375; -.
DR   PharmGKB; PA36213; -.
DR   eggNOG; KOG0201; Eukaryota.
DR   eggNOG; ENOG410XP9G; LUCA.
DR   GeneTree; ENSGT00810000125395; -.
DR   HOGENOM; HOG000234203; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q13188; -.
DR   KO; K04412; -.
DR   OMA; KQDSKLK; -.
DR   OrthoDB; EOG091G065P; -.
DR   PhylomeDB; Q13188; -.
DR   TreeFam; TF354217; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-2028269; Signaling by Hippo.
DR   SignaLink; Q13188; -.
DR   SIGNOR; Q13188; -.
DR   ChiTaRS; STK3; human.
DR   GeneWiki; STK3; -.
DR   GenomeRNAi; 6788; -.
DR   PMAP-CutDB; Q13188; -.
DR   PRO; PR:Q13188; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000104375; -.
DR   CleanEx; HS_STK3; -.
DR   ExpressionAtlas; Q13188; baseline and differential.
DR   Genevisible; Q13188; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; TAS:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0060706; P:cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; IEA:Ensembl.
DR   GO; GO:0003157; P:endocardium development; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0046621; P:negative regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0001841; P:neural tube formation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:MGI.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IGI:MGI.
DR   GO; GO:0060215; P:primitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:MGI.
DR   GO; GO:0060800; P:regulation of cell differentiation involved in embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR024205; Mst1_SARAH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR011524; SARAH_dom.
DR   Pfam; PF11629; Mst1_SARAH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS50951; SARAH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Coiled coil; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    491       Serine/threonine-protein kinase 3.
FT                                /FTId=PRO_0000086689.
FT   CHAIN         1    322       Serine/threonine-protein kinase 3 36kDa
FT                                subunit.
FT                                /FTId=PRO_0000413713.
FT   CHAIN       323    491       Serine/threonine-protein kinase 3 20kDa
FT                                subunit.
FT                                /FTId=PRO_0000413714.
FT   DOMAIN       27    278       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      437    484       SARAH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00310}.
FT   NP_BIND      33     41       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COILED      287    328       {ECO:0000255}.
FT   COILED      442    475       {ECO:0000255}.
FT   COMPBIAS    308    314       Poly-Glu.
FT   COMPBIAS    370    375       Poly-Glu.
FT   ACT_SITE    146    146       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      56     56       ATP.
FT   SITE        322    323       Cleavage; by caspase-3.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|Ref.7}.
FT   MOD_RES      15     15       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     117    117       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:20086174,
FT                                ECO:0000269|PubMed:20231902}.
FT   MOD_RES     180    180       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES     316    316       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     336    336       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     384    384       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:20086174}.
FT   MOD_RES     385    385       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     444    444       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ       1      8       MEQPPAPK -> MLQLMDSGITICLRNGAASVFKKKEWSTQ
FT                                GEENKQD (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054167.
FT   VARIANT      60     60       V -> L (in an ovarian clear cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041122.
FT   VARIANT     418    418       F -> C (in dbSNP:rs36047674).
FT                                /FTId=VAR_051670.
FT   MUTAGEN      56     56       K->R: Loss of activity.
FT                                {ECO:0000269|PubMed:16930133}.
FT   MUTAGEN     322    322       D->N: Resistant to proteolytic cleavage.
FT                                {ECO:0000269|PubMed:11278283}.
FT   CONFLICT     96     98       WIV -> YLY (in Ref. 8; CAA80909).
FT                                {ECO:0000305}.
FT   CONFLICT    121    121       D -> Y (in Ref. 8; CAA80909).
FT                                {ECO:0000305}.
FT   CONFLICT    203    203       D -> G (in Ref. 8; CAA80909).
FT                                {ECO:0000305}.
FT   CONFLICT    303    303       E -> D (in Ref. 1; AAC50386).
FT                                {ECO:0000305}.
FT   CONFLICT    332    334       ESV -> GEC (in Ref. 1; AAC50386).
FT                                {ECO:0000305}.
FT   HELIX        17     20       {ECO:0000244|PDB:4LGD}.
FT   HELIX        23     26       {ECO:0000244|PDB:4LG4}.
FT   STRAND       27     34       {ECO:0000244|PDB:4LG4}.
FT   STRAND       40     46       {ECO:0000244|PDB:4LG4}.
FT   TURN         47     49       {ECO:0000244|PDB:4LG4}.
FT   STRAND       52     58       {ECO:0000244|PDB:4LG4}.
FT   HELIX        64     76       {ECO:0000244|PDB:4LG4}.
FT   STRAND       85     91       {ECO:0000244|PDB:4LG4}.
FT   STRAND       94    100       {ECO:0000244|PDB:4LG4}.
FT   STRAND      103    106       {ECO:0000244|PDB:5DH3}.
FT   HELIX       107    114       {ECO:0000244|PDB:4LG4}.
FT   HELIX       120    139       {ECO:0000244|PDB:4LG4}.
FT   HELIX       149    151       {ECO:0000244|PDB:4LG4}.
FT   STRAND      152    154       {ECO:0000244|PDB:4LG4}.
FT   STRAND      160    162       {ECO:0000244|PDB:4LG4}.
FT   HELIX       170    172       {ECO:0000244|PDB:4LG4}.
FT   HELIX       175    182       {ECO:0000244|PDB:4LG4}.
FT   HELIX       185    187       {ECO:0000244|PDB:5DH3}.
FT   HELIX       190    195       {ECO:0000244|PDB:4LG4}.
FT   HELIX       201    216       {ECO:0000244|PDB:4LG4}.
FT   TURN        220    223       {ECO:0000244|PDB:4LG4}.
FT   HELIX       226    235       {ECO:0000244|PDB:4LG4}.
FT   HELIX       244    246       {ECO:0000244|PDB:4LG4}.
FT   HELIX       249    258       {ECO:0000244|PDB:4LG4}.
FT   HELIX       263    265       {ECO:0000244|PDB:4LG4}.
FT   HELIX       269    272       {ECO:0000244|PDB:4LG4}.
FT   HELIX       276    279       {ECO:0000244|PDB:4LG4}.
FT   HELIX       284    287       {ECO:0000244|PDB:4LG4}.
FT   HELIX       288    306       {ECO:0000244|PDB:4LG4}.
FT   STRAND      379    381       {ECO:0000244|PDB:5BRM}.
FT   HELIX       392    394       {ECO:0000244|PDB:5BRM}.
FT   TURN        395    397       {ECO:0000244|PDB:5BRM}.
FT   HELIX       436    440       {ECO:0000244|PDB:4L0N}.
FT   HELIX       445    483       {ECO:0000244|PDB:4L0N}.
SQ   SEQUENCE   491 AA;  56301 MW;  84F598ED3617292C CRC64;
     MEQPPAPKSK LKKLSEDSLT KQPEEVFDVL EKLGEGSYGS VFKAIHKESG QVVAIKQVPV
     ESDLQEIIKE ISIMQQCDSP YVVKYYGSYF KNTDLWIVME YCGAGSVSDI IRLRNKTLIE
     DEIATILKST LKGLEYLHFM RKIHRDIKAG NILLNTEGHA KLADFGVAGQ LTDTMAKRNT
     VIGTPFWMAP EVIQEIGYNC VADIWSLGIT SIEMAEGKPP YADIHPMRAI FMIPTNPPPT
     FRKPELWSDD FTDFVKKCLV KNPEQRATAT QLLQHPFIKN AKPVSILRDL ITEAMEIKAK
     RHEEQQRELE EEEENSDEDE LDSHTMVKTS VESVGTMRAT STMSEGAQTM IEHNSTMLES
     DLGTMVINSE DEEEEDGTMK RNATSPQVQR PSFMDYFDKQ DFKNKSHENC NQNMHEPFPM
     SKNVFPDNWK VPQDGDFDFL KNLSLEELQM RLKALDPMME REIEELRQRY TAKRQPILDA
     MDAKKRRQQN F
//
